Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Protagonist Therapeutics
Biotech
J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial
After being touted as a rival to BMS’ reigning psoriasis med Sotyktu for months, J&J’s IL-23 drug looks like it has a shot at taking the crown.
James Waldron
Sep 17, 2025 9:45am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu
Mar 10, 2025 7:30am
Takeda's $300M bet on Protagonist's blood cancer drug pays off
Mar 3, 2025 8:45am
J&J, Protagonist's oral psoriasis prospect scores in phase 3s
Nov 19, 2024 11:44am
Takeda plays Protagonist, paying $300M for blood disease pact
Jan 31, 2024 5:41pm
